Abstract:Polymer drug conjugates have demonstrated application potentials in optimizing chemotherapeutics. In this study a new bioconjugate, HA-ss-PTX, was designed and synthesized with cooperative dual characteristics of active tumor targeting and selective intracellular drug release. Paclitaxel (PTX) was covalently attached to hyaluronic acid (HA) with various sizes (MW 9.5, 35, 770 kDa); a cross-linker containing disulfide bond was also used to shield drug leakage in blood circulation and to achieve rapid drug release in tumor cells in response to glutathione. Incorporation of HA to the conjugate enhanced the capabilities of drug loading, intracellular endocytosis and tumor targeting of micelles in comparison to mPEG. HA molecular weight showed significant effect on properties and antitumor efficacy of the synthesized conjugates. Intracellular uptake of HA-ss-PTX toward MCF-7 cells was mediated by CD44-caveolae-mediated endocytosis. Compared to Taxol and mPEG-ss-PTX, HA9.5-ss-PTX demonstrated improved tumor growth inhibition in vivo with a TIR of 83.27 +/- 5.20%. It was concluded that HA9.5-ss-PTX achieved rapid intracellular release of PTX and enhanced its therapeutic efficacy, thus providing a platform for specific drug targeting and controlled intracellular release in chemotherapeutics.Statement of SignificancePolymer drug conjugates, promising nanomedicines, still face some technical challenges including a lack of specific targeting and rapid intracellular drug release at the target site. In this manuscript we designed and constructed a novel bioconjugate HA-ss-PTX, which possessed coordinated dual characteristics of active tumor targeting and selective intracellular drug release. Redox-responsive disulfide bond was introduced to the conjugate to shield drug leakage in blood circulation and to achieve rapid drug release at tumor site in response to reductant like glutathione. Paclitaxel was selected as a model drug to be covalently attached to hyaluronic acid (HA) with various sizes to elucidate the structure activity relationship and to address whether HA could substitute PEG as a carrier for polymeric conjugates. Based on a series of in vitro and in vivo experiments, HA-ss-PTX performed well in drug loading, cellular internalization, tumor targeting by entering tumor cells via CD44-caveolae-mediated endocytosis and rapidly release drug at target in the presence of GSH. One of the key issues in clinical oncology is to enhance drug delivery efficacy while minimizing side effects. The study indicated that this new polymeric conjugate system would be useful in delivering anticancer agents to improve therapeutic efficacy and to minimize adverse effects, thus providing a platform for specific drug targeting and controlled intracellular release in chemotherapeutics. (C) 2015 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.

Injectable pH and redox dual responsive hydrogels based on self-assembled peptides for anti-tumor drug delivery

Short and simple peptide-based pH-sensitive hydrogel for antitumor drug delivery

Paclitaxel-loaded Ph Responsive Hydrogel Based on Self-Assembled Peptides for Tumor Targeting

pH-Sensitive Peptide Hydrogels as a Combination Drug Delivery System for Cancer Treatment

Redox-Sensitive Ultrashort Peptide Hydrogel with Tunable Mechanical Properties for Anti-Tumor Drug Delivery

Fabrication of injectable hydrogels from an anticancer peptide for local therapeutic delivery and synergistic photothermal-chemotherapy

Controlled release of paclitaxel from a self-assembling peptide hydrogel formed in situ and antitumor study in vitro.

Targeted Chemotherapy for Breast Cancer Using an Intelligent Doxorubicin-Loaded Hexapeptide Hydrogel.

A reconstituted thermosensitive hydrogel system based on paclitaxel-loaded amphiphilic copolymer nanoparticles and antitumor efficacy.

Doxorubicin-reinforced Supramolecular Hydrogels of RGD-derived Peptide Conjugates for Ph-Responsive Drug Delivery

Intracellular Delivery and Antitumor Effects of a Redox-Responsive Polymeric Paclitaxel Conjugate Based on Hyaluronic Acid.

In situ forming an injectable hyaluronic acid hydrogel for drug delivery and synergistic tumor therapy

Self-assembly of pH-responsive dextran-g-poly(lactide-co-glycolide)-g-histidine copolymer micelles for intracellular delivery of paclitaxel and its antitumor activity

Redox-sensitive hyaluronic acid–paclitaxel conjugate micelles with high physical drug loading for efficient tumor therapy

Redox-responsive Supramolecular Hydrogel Based on 10-Hydroxy Camptothecin-Peptide Covalent Conjugates with High Loading Capacity for Drug Delivery

Poly(cystine-PCL) based pH/redox dual-responsive nanocarriers for enhanced tumor therapy.

An injectable thermosensitive hydrogel self-supported by nanoparticles of PEGylated amino-modified PCL for enhanced local tumor chemotherapy

Stimuli-responsive Gel-Micelles with Flexible Modulation of Drug Release for Maximized Antitumor Efficacy

Ph Triggered Injectable Amphiphilic Hydrogel Containing Doxorubicin and Paclitaxel

Redox- and MMP-2-sensitive Drug Delivery Nanoparticles Based on Gelatin and Albumin for Tumor Targeted Delivery of Paclitaxel.

A pH and reduction dual-sensitive polymeric nanomicelle for tumor microenvironment triggered cellular uptake and controlled intracellular drug release.